TaiwanJ Pharmaceuticals Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 15.36 million compared to TWD 22.06 million a year ago. Net loss was TWD 92.47 million compared to TWD 12.42 million a year ago.

Basic loss per share from continuing operations was TWD 1.23 compared to TWD 0.17 a year ago. Diluted loss per share from continuing operations was TWD 1.23 compared to TWD 0.17 a year ago.